Physician profile
Fady Asslo
NPI 1659653723
$2,065.91
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $423 · 2020: $17.66 · 2021: $147 · 2022: $326 · 2023: $885 · 2024: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,131 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,131.33 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $827.78 | 2019-2024 | Linzess, Viberzi, Skyrizi |
| Boston Scientific Corporation | $291.27 | 2019-2023 | Axios |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $164.70 | 2021-2023 | Xifaxan |
| Apollo Endosurgery US INC | $134.32 | 2023 | Overstitch Endoscopic Suturing System |
| Medical Device Business Services, INC. | $124.83 | 2019 | |
| Intercept Pharmaceuticals, INC. | $103.80 | 2024 | |
| Genzyme Corporation | $103.73 | 2024 | |
| Janssen Biotech, INC. | $69.86 | 2021-2023 | Stelara |
| Regeneron Healthcare Solutions, INC. | $65.56 | 2023 | Dupixent |
| Allergan, INC. | $64.29 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $58.17 | 2019 | |
| Shire North American Group INC | $23.00 | 2019 | |
| Ethicon US, LLC | $19.30 | 2019 | |
| Endogastric Solutions, INC | $15.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fady Asslo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.